Quantitative MR Imaging R₂ Relaxometry in Elderly Participants Reporting Memory Loss

References

1. ↵
   Connor JR, Snyder BS, Beard JL, et al. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer’s disease. J Neurosci Res 1992;31:327–35

   CrossRefPubMedWeb of Science
2. ↵
   Cornett CR, Markesbery WR, Ehmann WD. Imbalances of trace elements related to oxidative damage in Alzheimer’s disease brain. NeuroToxicology 1998;19:339–46

   PubMedWeb of Science
3. ↵
   Deibel MA, Ehmann WD, Markesbery WR. Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer’s disease: possible relation to oxidative stress. J Neurol Sci 1996;143:137–42

   CrossRefPubMedWeb of Science
4. ↵
   Loeffler DA, Connor JR, Juneau PL, et al. Transferrin and iron in normal, Alzheimer’s disease, and Parkinson’s disease brain regions. J Neurochem 1995;65:710–16

   PubMedWeb of Science
5. ↵
   Thompson CM, Markesbery WR, Ehmann WD, et al. Regional brain trace element studies in Alzheimer’s disease. Neurotoxicology 1988;9:1–8

   PubMedWeb of Science
6. ↵
   LeVine SM. Iron deposits in multiple sclerosis and Alzheimer’s disease brains. Brain Res 1997;760:298–303

   CrossRefPubMedWeb of Science
7. ↵
   Smith MA, Harris PL, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 1997;94:9866–68

   Abstract/FREE Full Text
8. ↵
   Mantyh PW, Ghilardi JR, Rogers S, et al. Aluminum, iron, and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide. J Neurochem 1993;61:1171–74

   CrossRefPubMedWeb of Science
9. ↵
   Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995;216:702–707

   CrossRefPubMedWeb of Science
10. ↵
    Englund E, Brun A, Persson B. Correlations between histopathologic white matter changes and proton MR relaxation times in dementia. Alzheimer Dis Assoc Disord 1987;1:156–70

    CrossRefPubMed
11. ↵
    Sjobeck M, Englund E. Glial levels determine severity of white matter disease in Alzheimer’s disease: a neuropathological study of glial changes. Neuropathol Appl Neurobiol 2003;29:159–69

    CrossRefPubMed
12. ↵
    Englund E, Brun A, Alling C. White matter changes in dementia of Alzheimer’s type: biochemical and neuropathological correlates. Brain 1998;111:1425–39
13. ↵
    Soderberg M, Edlund C, Alafuzoff I, et al. Lipid composition in different regions of the brain in Alzheimer’s disease/senile dementia of Alzheimer’s type. J Neurochem 1992;59:1646–53

    CrossRefPubMed
14. ↵
    Bartzokis G, Cummings J, Sultzer D, et al. White matter structural integrity in healthy aging adults and patients with Alzheimer disease. Arch Neurol 2003;60:393–98

    CrossRefPubMedWeb of Science
15. ↵
    Barber R, Scheltens P, Gholkar A, et al. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatry 1999;67:66–72

    Abstract/FREE Full Text
16. ↵
    Varma AR, Laitt R, Lloyd JJ, et al. Diagnostic value of high signal abnormalities on T2 weighted MRI in the differentiation of Alzheimer’s, frontotemporal and vascular dementias. Acta Neurol Scand 2002;105:355–64

    CrossRefPubMed
17. ↵
    Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer’s disease. Neurobiol Aging 2004;25:5–18

    CrossRefPubMedWeb of Science
18. ↵
    Roher AE, Weiss N, Kokjohn TA, et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry 2002;41:11080–90

    CrossRefPubMed
19. ↵
    Brittenham GM, Badman DG, National Institute of Digestive, Kidney Diseases Workshop. Noninvasive measurement of iron: report of an NIDDK workshop. Blood 2003;101:15–19

    Abstract/FREE Full Text
20. ↵
    Besson JA, Best PV, Skinner ER. Post-mortem proton magnetic resonance spectrometric measures of brain regions in patients with a pathological diagnosis of Alzheimer’s disease and multi-infarct dementia. Br J Psychiatry 1992;160:187–90

    Abstract/FREE Full Text
21. ↵
    Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human body. J Neurochem 1958;3:41–51

    CrossRefPubMedWeb of Science
22. ↵
    Breger RK, Rimm AA, Fischer ME, et al. T1 and T2 measurements on a 1.5-T commercial MR imager. Radiology 1989;171:273–76

    PubMedWeb of Science
23. ↵
    Bartzokis G, Sultzer D, Mintz J, et al. In-vivo evaluation of brain iron in Alzheimer’s disease and normal subjects using MRI. Biol Psychiatry 1994;35:480–87

    CrossRefPubMedWeb of Science
24. ↵
    Bartzokis G, Tishler TA. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer’s and Huntington’s disease. Cell Mol Biol 2000;46:821–33

    PubMedWeb of Science
25. ↵
    Laasko MP, Partanen K, Soininen H, et al. MR T2 relaxometry in Alzheimer’s disease and age-associated memory impairment. Neurobiol Aging 1996;17:535–40

    PubMedWeb of Science
26. ↵
    Kirsch SJ, Jacobs RW, Butcher LL, et al. Prolongation of magnetic resonance T2 time in hippocampus of human patients marks the presence and severity of Alzheimer’s disease. Neurosci Lett 1992;134:187–90

    CrossRefPubMedWeb of Science
27. ↵
    Pitkanen A, Laasko M, Kalviainen R, et al. Severity of hippocampal atrophy correlates with the prolongation of MRI T2 relaxation time in temporal lobe epilepsy but not Alzheimer’s disease. Neurology 1996;46:1724–30

    Abstract/FREE Full Text
28. ↵
    Wang H, Yuan H, Shu L, et al. Prolongation of T2 relaxation times of hippocampus and amygdala in Alzheimer’s disease. Neurosci Lett 2004;363:150–53

    CrossRefPubMed
29. ↵
    Campeau NG, Petersen RC, Felmlee JP, et al. Hippocampal transverse relaxation times in patients with Alzheimer disease. Radiology 1997;205:197–201

    PubMed
30. ↵
    St. Pierre TG, Clark PR, Chua-anusorn W. Single spin-echo proton transverse relaxometry of iron-loaded liver. NMR Biomed 2004;17:446–58

    CrossRefPubMed
31. ↵
    Nunomura A, Perry G, Aliev G, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759–67

    PubMedWeb of Science
32. ↵
    Bishop GM, Robinson SR, Liu Q, et al. Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 2002;24:184–87

    CrossRefPubMedWeb of Science
33. ↵
    de Groot JC, de Leeuw FE, Oudkerk M, et al. Cerebral white matter lesions and subjective cognitive dysfunction: the Rotterdam Scan Study. Neurology 2001;56:1539–45

    Abstract/FREE Full Text
34. ↵
    de la Monte SM. Quantitation of cerebral atrophy in preclinical and end-stage Alzheimer’s disease. Ann Neurol 1989;25:450–59

    CrossRefPubMedWeb of Science
35. ↵
    Santyr GE. Magnetization transfer effects in multislice MR imaging. Magn Reson Imaging 1993;11:521–32

    CrossRefPubMedWeb of Science
36. ↵
    Vymazal J, Righini A, Brooks RA, et al. T1 and T2 in the brain of healthy subjects, patients with Parkinson disease, and patients with multiple system atrophy: Relation to iron content. Radiology 1999;211:489–95

    PubMedWeb of Science
37. ↵
    Hikita T, Abe K, Sakoda S, et al. Determination of transverse relaxation rate for estimating iron deposits in central nervous system. Neurosci Res 2005;51:67–71

    CrossRefPubMed
38. ↵
    Gelman N, Gorell JM, Barker PB, et al. MR imaging of human brain at 3.0 T: preliminary report on transverse relaxation rates and relation to estimated iron content. Radiology 1999;210:759–67

    PubMedWeb of Science
39. ↵
    Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson’s disease and Alzheimer’s disease. Dementia 1993;4:61–65
40. ↵
    Delacourte A, David JP, Sergeant N, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. Neurology 1999;52:1158–65

    Abstract/FREE Full Text
41. ↵
    Huesgen CT, Burger PC, Crain BJ, et al. In vitro MR microscopy of the hippocampus in Alzheimer’s disease. Neurology 1993;43:145–52

    Abstract/FREE Full Text
42. ↵
    Reinikainen KJ, Pitkanen A, Riekkinen PJ. 2′,3′-cyclic nucleotide-3′-phosphodiesterase activity as an index of myelin in the post-mortem brains of patients with Alzheimer’s disease. Neurosci Lett 1989;106:229–32

    PubMed
43. ↵
    Brooks RA, Vymazal J, Bulte JWM, et al. Comparison of T2 relaxation in blood, brain and ferritin. J Magn Reson Imaging 1995;4:446–50
44. ↵
    Parsey RV, Krishnan KR. Quantitative analysis of T2 signal intensities in Alzheimer’s disease. Psychiatry Res 1998;82:181–85

    PubMed
45. ↵
    Morris CM, Candy JM, Oakley AE, et al. Histochemical distribution of non-haem iron in the human brain. Acta Anatomica 1992;144:235–57

    PubMedWeb of Science
46. ↵
    Fernando MS, O’Brien JT, Perry RH, et al. Comparison of the pathology of cerebral white matter with post-mortem magnetic resonance imaging (MRI) in the elderly brain. Neuropathol Appl Neurobiol 2004;30:385–95

    CrossRefPubMedWeb of Science
47. ↵
    Fennema-Notestine C, Archibald SL, Jacobson MW, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology 2004;63:989–95

    Abstract/FREE Full Text
48. ↵
    Whittall KP, MacKay AL, Li DK, et al. Normal-appearing white matter in multiple sclerosis has heterogeneous, diffusely prolonged T2. Magn Reson Med 2002;47:403–408

    CrossRefPubMedWeb of Science
49. ↵
    Bakshi R, Benedict RH, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 2002;59:62–68

    CrossRefPubMedWeb of Science
50. ↵
    Cada A, de la Torre JC, Gonzalez-Lima F. Chronic cerebrovascular ischemia in aged rats: effects on brain metabolic capacity and behavior. Neurobiol Aging 2000;21:225–33

    PubMed
51. ↵
    Baloyannis SJ, Costa V, Michmizos D. Mitochondrial alterations in Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2004;19:89–93

    Abstract/FREE Full Text
52. ↵
    Kopelman MD. Disorders of memory. Brain 2002;125:2152–90

    Abstract/FREE Full Text
53. ↵
    Braak H, Braak E. Alzheimer’s disease affects limbic nuclei of the thalamus. Acta Neuropathol 1991;81:261–68

    CrossRefPubMedWeb of Science